Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection.
COVID-19
COVID-19 and anti-viral agents
Coronavirus
TQ formula
Thymoquinone TQ
fatty acids
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
09
2023
accepted:
15
01
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
21
2
2024
Statut:
epublish
Résumé
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants
Identifiants
pubmed: 38379905
doi: 10.3389/fphar.2024.1291212
pii: 1291212
pmc: PMC10876831
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1291212Informations de copyright
Copyright © 2024 Maen, Gok Yavuz, Mohamed, Esmail, Lu, Mohamed, Azmi, Kaseb, Kasseb, Li, Gocio, Kocak, Selim, Ma and Kaseb.
Déclaration de conflit d'intérêts
Author JL was employed by Codex BioSolutions Inc. Authors MoK, OK, and MG were employed by Novatek Pharmaceuticals, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.